Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 53 4 2015 04 15 199 203 EN Katayoun Ziari Department of Pathology, Be'sat Hospital, AJA University of Medical Sciences, Tehran, Iran. Ebrahim Soleymani Department of Pathology, Be'sat Hospital, AJA University of Medical Sciences, Tehran, Iran. Kamyab Alizadeh Department of Pathology, Be'sat Hospital, AJA University of Medical Sciences, Tehran, Iran. 2015 10 11 The aim of this study was to determine the prognosis and survival for patients with borderlineovarian tumor (BOT). A retrospective review of 30 patients with serous andmucinous BOT treated at or referred to our institution was performed. Fifteenpatients (50%) had serous, and the others had mucinous BOT. About 86% of allpatients in both groups were in stage I of the disease. The recurrent disease occurredin 7% and 21% of serous and mucinous tumors, respectively. All recurrences,except one in mucinous tumors, were found in advance stage disease. After amean of 37 and 52 months follow-up, the overall survival was 100% and 93%, anddisease-free survival was 93% and 79% for serous and mucinous tumors,respectively. In this series, advanced stage was associated with poorprognosis. However, to obtain more accurate information further studies withnumber of patients and longer follow-up is recommended. https://acta.tums.ac.ir/index.php/acta/article/view/4907 https://acta.tums.ac.ir/index.php/acta/article/download/4907/4397